Mirja Harms

Albert Einstein Allee 23
Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.

A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.

Journal: Scientific reports

Published: August 08, 2025

Targeting the CXCL12/CXCR4 pathway by an optimized derivative or EPI-X4 preserves chondrocyte function and offers a novel therapeutic approach in rheumatic diseases.

Targeting the CXCL12/CXCR4 pathway by an optimized derivative or EPI-X4 preserves chondrocyte function and offers a novel therapeutic approach in rheumatic diseases.

Journal: Arthritis research & therapy

Published: June 18, 2025

GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration.

GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration.

Journal: Cell communication and signaling : CCS

Published: February 11, 2025

CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma.

CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma.

Journal: International journal of molecular sciences

Published: November 27, 2024

Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4.

Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4.

Journal: ChemMedChem

Published: September 28, 2024

A naturally occurring 22-amino acid fragment of human hemoglobin A inhibits autophagy and HIV-1.

A naturally occurring 22-amino acid fragment of human hemoglobin A inhibits autophagy and HIV-1.

Journal: Cellular and molecular life sciences : CMLS

Published: July 03, 2024

An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia.

An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia.

Journal: International journal of molecular sciences

Published: May 16, 2024

Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability.

Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: March 19, 2024

Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.

Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.

Journal: Journal of medicinal chemistry

Published: November 08, 2023

Peptide Bispecifics Inhibiting HIV-1 Infection by an Orthogonal Chemical and Supramolecular Strategy.

Peptide Bispecifics Inhibiting HIV-1 Infection by an Orthogonal Chemical and Supramolecular Strategy.

Journal: Bioconjugate chemistry

Published: September 04, 2023

Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection.

Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection.

Journal: Science advances

Published: July 05, 2023

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications.

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications.

Journal: Journal of medicinal chemistry

Published: June 16, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026